Stock 4013 DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dr. Sulaiman Al Habib Medical Services Group Company

Equities

4013

SA1510P1UMH1

Healthcare Facilities & Services

End-of-day quote Saudi Arabian S.E.
Other stock markets
 06:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
315 SAR 0.00% Intraday chart for Dr. Sulaiman Al Habib Medical Services Group Company +0.06% +10.92%
Mar. 24 Alandalus Property, Dr. Sulaiman Al Habib Medical Services Receive Saudi License for Hospital Operations MT
Feb. 20 Dr. Sulaiman Al Habib Medical Services Group Company Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 38,150 56,490 77,210 99,400 110,250 - -
Enterprise Value (EV) 1 38,150 56,609 77,663 101,963 116,093 116,166 117,366
P/E ratio 36.1 x 41.1 x 46.7 x 48.5 x 50.6 x 40.4 x 34.8 x
Yield 1.38% 1.67% - - 1.2% 1.73% 1.75%
Capitalization / Revenue 6.51 x 7.79 x 9.29 x 10.5 x 9.58 x 7.47 x 7.05 x
EV / Revenue 6.51 x 7.81 x 9.34 x 10.7 x 10.1 x 7.87 x 7.51 x
EV / EBITDA 26.6 x 31.8 x 38.6 x 42.3 x 40.9 x 33.2 x 28.9 x
EV / FCF 26.9 x 60.9 x 58.4 x -403 x 151 x 53.6 x 36.5 x
FCF Yield 3.72% 1.64% 1.71% -0.25% 0.66% 1.87% 2.74%
Price to Book 7.77 x 10.6 x 13.1 x 15.3 x 15.5 x 13.9 x 12.3 x
Nbr of stocks (in thousands) 350,000 350,000 350,000 350,000 350,000 - -
Reference price 2 109.0 161.4 220.6 284.0 315.0 315.0 315.0
Announcement Date 2/21/21 2/20/22 2/21/23 2/20/24 - - -
1SAR in Million2SAR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,862 7,250 8,311 9,508 11,513 14,756 15,636
EBITDA 1 1,433 1,781 2,010 2,408 2,841 3,498 4,062
EBIT 1 1,115 1,466 1,700 2,096 2,291 2,981 3,448
Operating Margin 19.02% 20.22% 20.46% 22.04% 19.9% 20.2% 22.05%
Earnings before Tax (EBT) 1 1,128 1,491 1,797 2,170 2,430 3,036 3,655
Net income 1 1,055 1,377 1,651 2,046 2,326 2,805 3,220
Net margin 18.01% 18.99% 19.86% 21.52% 20.2% 19.01% 20.59%
EPS 2 3.020 3.930 4.720 5.850 6.220 7.800 9.053
Free Cash Flow 1 1,420 929.3 1,330 -252.7 770 2,167 3,218
FCF margin 24.23% 12.82% 16.01% -2.66% 6.69% 14.69% 20.58%
FCF Conversion (EBITDA) 99.14% 52.18% 66.19% - 27.11% 61.95% 79.2%
FCF Conversion (Net income) 134.57% 67.5% 80.59% - 33.11% 77.26% 99.92%
Dividend per Share 2 1.500 2.700 - - 3.787 5.456 5.500
Announcement Date 2/21/21 2/20/22 2/21/23 2/20/24 - - -
1SAR in Million2SAR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1
Net sales 1 1,836 1,968 1,991 2,014 2,052 2,254 2,307 2,272 2,443 2,486 2,580
EBITDA - - 498.7 - - 505.3 - 577 - - -
EBIT 1 380.5 396.3 422.1 414.7 436.1 427.6 510.6 498.8 552.1 534.2 548.5
Operating Margin 20.72% 20.13% 21.2% 20.59% 21.25% 18.97% 22.13% 21.95% 22.6% 21.48% 21.26%
Earnings before Tax (EBT) - - - - - - - - - - -
Net income 1 348.6 383.6 390.5 398.1 420.6 441.5 489.3 487 544.8 491 533.3
Net margin 18.98% 19.49% 19.61% 19.77% 20.5% 19.59% 21.21% 21.43% 22.3% 19.75% 20.67%
EPS 1.000 1.090 - - 1.200 1.260 1.400 1.390 1.560 1.500 -
Dividend per Share - - - - - - - - - - -
Announcement Date 10/24/21 2/20/22 4/24/22 8/7/22 10/23/22 2/21/23 5/7/23 8/6/23 10/30/23 2/20/24 -
1SAR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 119 453 2,563 5,843 5,916 7,116
Net Cash position 1 - - - - - - -
Leverage (Debt/EBITDA) - 0.0667 x 0.2255 x 1.064 x 2.057 x 1.691 x 1.752 x
Free Cash Flow 1 1,420 929 1,330 -253 770 2,167 3,218
ROE (net income / shareholders' equity) 22.7% 26.9% 29.4% 33.1% 30.9% 35.7% 37.2%
ROA (Net income/ Total Assets) 11.8% 13.6% 14.1% 14.4% 15.6% 17.5% 19.3%
Assets 1 8,974 10,154 11,706 14,191 14,955 16,000 16,684
Book Value Per Share 2 14.00 15.30 16.80 18.50 20.40 22.70 25.50
Cash Flow per Share 2 - - - 9.270 7.200 8.700 11.10
Capex 1 758 1,254 1,513 3,497 4,200 1,403 988
Capex / Sales 12.93% 17.29% 18.21% 36.78% 36.48% 9.51% 6.32%
Announcement Date 2/21/21 2/20/22 2/21/23 2/20/24 - - -
1SAR in Million2SAR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Dr. Sulaiman Al Habib Medical Services Group Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
315 SAR
Average target price
291.6 SAR
Spread / Average Target
-7.43%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+10.92% 29.4B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-14.92% 84.68B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+13.30% 81.12B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-12.71% 16.73B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-3.06% 16.36B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-2.63% 14.92B
PURE HEALTH HOLDING Stock Pure Health Holding
-31.75% 11.77B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
-1.42% 11.72B
DAVITA INC. Stock DaVita Inc.
+27.44% 11.71B
EUROFINS SCIENTIFIC SE Stock Eurofins Scientific SE
-3.97% 11.66B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. 4013 Stock
  4. Financials Dr. Sulaiman Al Habib Medical Services Group Company